- Details
- Phillip Koo interviews Ken Herrmann about his presentation focusing on a predictive model for 177Lu-PSMA-617. Herrmann explains the difference between a prognostic tool, which indicates a patient's overall prognosis, and a predictive tool that specifies whether a patient is likely to benefit from a particular therapy. He presents a model based on data from the Vision trial and explains how this mo...
|
- Details
- Tanya Dorff shares her team’s insights on research into CAR T therapy targeting Prostate Stem Cell Antigen (PSCA). Their analysis shows promise in managing advanced castration-resistant prostate cancer. However, this treatment also presents challenges, including the issue of dose escalation due to the occurrence of high-grade cystitis, a complication encountered during the trials. In response, Dor...
|
- Details
- Pedro Barata and Brian Rini unpack the findings and implications of the KEYNOTE-426 trial. The trial assessed the efficacy of a pembrolizumab and axitinib regimen in advanced clear cell kidney cancer, contrasting it with the then-standard sunitinib monotherapy. The KEYNOTE-426 trial's success contributed to changing the standard of care in this field. It demonstrated superior response rates and pr...
|
- Details
- In an interview with Alicia Morgans, Karim Fizazi discusses cohort two of the TALAPRO-2 study. The cohort, which consists of nearly 400 men with DNA repair defects, proves highly insightful for prostate cancer research. Professor Fizazi reveals that the cohort’s results showed a 55% reduction in the risk of progression or death, with patients having BRCA1 and BRCA2 alterations showing particularly...
|
- Details
- In a discussion between Alicia Morgans and Karim Fizazi, they explore the quality of life outcomes from the VISION trial, published in Lancet Oncology. This Phase III trial examines the effects of Lutetium-PSMA-617 (also known as Pluvicto) on heavily pretreated metastatic castration-resistant prostate cancer patients. The study demonstrates a significant 38% reduction in the risk of death. Despite...
|
- Details
- Alicia Morgans speaks with Cora Sternberg about precision medicine's transformative impact on prostate cancer treatment. A key topic is the TALAPRO-2 study, which examines the efficacy of the PARP inhibitor talazoparib in combination with enzalutamide in treating metastatic castration-resistant prostate cancer (CRPC). The study's positive findings suggest significant benefits for patients with BRC...
|
- Details
- Alicia Morgans engages with Scott Tagawa regarding his team's presentations on a phase one study highlighting the combination of an alpha and beta emitter targeting PSMA in prostate cancer. Despite being a preliminary trial, the research reveals promising safety profiles for the combined approaches, along with potential early efficacy signals, such as PSA reductions and circulating tumor cell conv...
|
- Details
- In this discussion, Pedro Barata interviews Dena Battle, who discusses a presentation centered around a survey conducted by Kidney Cancer Research Alliance (KCCure) to understand patient perspectives on kidney cancer treatment. The survey, which received over a thousand responses, specifically targeted metastatic patients and focused on their perceptions of successful treatment, therapy selection,...
|
- Details
- Daniel George and Alicia Morgans explore the groundbreaking results of the PANTHER study. The study addresses an enduring gap in clinical trials concerning black patients, who are disproportionately affected by prostate cancer. The PANTHER study investigates the effects of a novel combination of hormonal therapies, apalutamide and abiraterone, in castrate-resistant prostate cancer. Intriguingly, t...
|
- Details
- Alicia Morgans interviews Praful Ravi about his abstract presentation concerning PSA nadir within the ICECaP data set. ICECaP, a comprehensive data repository of individual patient data from more than 40 randomized trials conducted in localized prostate cancer, reveals that metastasis-free survival (MFS) is a proven surrogate for overall survival. In their study, Ravi and his team leveraged the IC...
|
